Ready 8-Ks
2
Latest filing
September 24, 2026, 9:19 AM ET
Top materiality
0.80
Event mix
other_material ×1 · m_and_a ×1
Sentiment
1 pos · 0 neg · 1 neu
Recent 8-K filings for CLYD
Highest-materiality recent filing
Balomenib Phase 1b shows durable HbA1c improvement; Merger closing extended to Oct 31
- Merger closing date for Clywedog acquisition amended to Oct 31, 2026 (or earlier mutual agreement); End Date also Oct 31, 2026.
- Phase 1b: placebo-adjusted HbA1c -0.77% at Week 12 (p<0.01) and -0.70% at Week 16 (p<0.05) after 3-week dosing.
-
Balomenib Phase 1b shows durable HbA1c improvement; Merger closing extended to Oct 31
Merger closing date for Clywedog acquisition amended to Oct 31, 2026 (or earlier mutual agreement); End Date also Oct 31, 2026.
-
Beacon Topco completes Barinthus Bio acquisition; launches $15M share tender offer
Acquisition of Barinthus Biotherapeutics closed via UK scheme of arrangement effective Sept 9, 2026; Barinthus now wholly-owned subsidiary.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.73 · Most common event other_material